Evidence map›Paper›PMID 38564754›Full record

ArticleChannels (Austin, Tex.)2024

Novel protocol for multiple-dose oral administration of the L-type Ca

Tamara Theiner, Nadine J Ortner, Herbert Oberacher, Gospava Stojanovic, Petronel Tuluc, Jörg Striessnig

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Channels (Austin, Tex.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tamara TheinerDepartment of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
Nadine J OrtnerDepartment of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
Herbert OberacherInstitute of Legal Medicine and Core Facility Metabolomics, Medical University of Innsbruck, Innsbruck, Austria.
Gospava StojanovicDepartment of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
Petronel TulucDepartment of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.
Jörg StriessnigDepartment of Pharmacology and Toxicology, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-9406-7120
Universität Innsbruck · ATInnsbruck Medical University · AT

Funding

Austrian Science Fund FWF P 35722
6 · The paper itself

Abstract

Studies in genetically modified animals and human genetics have recently provided new insight into the role of voltage-gated L-type Ca

Indexed as

Calcium Channel BlockersCalcium Channels, L-TypeAdministration, OralAnimalsHumansIsradipineMiceCalcium Channel BlockersCalcium Channels, L-TypeIsradipineCalcium channel blockersdihydropyridinesdrug administrationpharmacokineticsvoltage-gated calcium channels

Identifiers

PMID38564754
PMCPMC10989688
OpenAlexW4393574526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.